Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales. July 28 (Reuters) - Merck & Co Inc's quarterly profit blew past analysts' estimates on Friday as sales of its key immuno-oncology drug Keytruda nearly tripled. Sales of Keytruda, which works by.